Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Prostate Cancer

Free Subscription Articles published in Prostate Retrieve available abstracts of 250 articles: HTML format Text format

Single Articles

March 2019
1. OH M, Alkhushaym N, Fallatah S, Althaghfi A, et al
   The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis.
   Prostate. 2019 Mar 22. doi: 10.1002/pros.23795.
   PubMed     Text format     Abstract available
   
   
   
2. YUAN L, Huang X, Zhou K, Zhu X, et al
   Sea cucumber extract TBL-12 inhibits the proliferation, migration, and invasion of human prostate cancer cells through the p38 mitogen-activated protein kinase and intrinsic caspase apoptosis pathway.
   Prostate. 2019 Mar 19. doi: 10.1002/pros.23788.
   PubMed     Text format     Abstract available
   
   
   
3. JAGARLAMUDI KK, Zupan M, Kumer K, Fabjan T, et al
   The combination of AroCell TK 210 ELISA with Prostate Health Index or prostate-specific antigen density can improve the ability to differentiate prostate cancer from noncancerous conditions.
   Prostate. 2019 Mar 19. doi: 10.1002/pros.23791.
   PubMed     Text format     Abstract available
   
   
   
4. SCHWEIZER MT, Gulati R, Beightol M, Konnick EQ, et al
   Clinical determinants for successful circulating tumor DNA analysis in prostate cancer.
   Prostate. 2019 Mar 13. doi: 10.1002/pros.23778.
   PubMed     Text format     Abstract available
   
   
   
5. WANG X, Qi M, Zhang J, Sun X, et al
   Differential response to neoadjuvant hormonal therapy in prostate cancer: Predictive morphological parameters and molecular markers.
   Prostate. 2019 Mar 2. doi: 10.1002/pros.23777.
   PubMed     Text format     Abstract available
   
   
   February 2019
6. LEE SI, Roney MSI, Park JH, Baek JY, et al
   Dopamine receptor antagonists induce differentiation of PC-3 human prostate cancer cell-derived cancer stem cell-like cells.
   Prostate. 2019 Feb 28. doi: 10.1002/pros.23779.
   PubMed     Text format     Abstract available
   
   
   
7. XUE YN, Yu BB, Liu YN, Guo R, et al
   Zinc promotes prostate cancer cell chemosensitivity to paclitaxel by inhibiting epithelial-mesenchymal transition and inducing apoptosis.
   Prostate. 2019 Feb 3. doi: 10.1002/pros.23772.
   PubMed     Text format     Abstract available
   
   
   
8. XU Y, Song Q, Pascal LE, Zhong M, et al
   DHX15 is up-regulated in castration-resistant prostate cancer and required for androgen receptor sensitivity to low DHT concentrations.
   Prostate. 2019 Feb 3. doi: 10.1002/pros.23773.
   PubMed     Text format     Abstract available
   
   
   January 2019
9. GAUR S, Gross ME, Liao CP, Qian B, et al
   Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells.
   Prostate. 2019 Jan 28. doi: 10.1002/pros.23774.
   PubMed     Text format     Abstract available
   
   
   
10. CHOI YH, Han DH, Kim SW, Kim MJ, et al
    A randomized, double-blind, placebo-controlled trial to evaluate the role of curcumin in prostate cancer patients with intermittent androgen deprivation.
    Prostate. 2019 Jan 22. doi: 10.1002/pros.23766.
    PubMed     Text format     Abstract available
    
    
    
11. GHINEA N, Robin B, Pichon C, Leclere R, et al
    Vasa nervorum angiogenesis in prostate cancer with perineural invasion.
    Prostate. 2019 Jan 20. doi: 10.1002/pros.23771.
    PubMed     Text format     Abstract available
    
    
    
12. LI C, He C, Xu Y, Xu H, et al
    Alternol eliminates excessive ATP production by disturbing Krebs cycle in prostate cancer.
    Prostate. 2019 Jan 20. doi: 10.1002/pros.23767.
    PubMed     Text format     Abstract available
    
    
    
13. PETRYLAK DP, Kantoff P, Vogelzang NJ, Mega A, et al
    Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer.
    Prostate. 2019 Jan 20. doi: 10.1002/pros.23765.
    PubMed     Text format     Abstract available
    
    
    
14. JOENTAUSTA RM, Rannikko A, Murtola TJ
    Prostate cancer survival among statin users after prostatectomy in a Finnish nationwide cohort.
    Prostate. 2019 Jan 16. doi: 10.1002/pros.23768.
    PubMed     Text format     Abstract available
    
    
    
15. LIU Y, Wu X, Jiang H
    Combined maternal and post-weaning high fat diet inhibits male offspring's prostate cancer tumorigenesis in transgenic adenocarcinoma of mouse prostate model.
    Prostate. 2019 Jan 6. doi: 10.1002/pros.23760.
    PubMed     Text format     Abstract available
    
    
    
16. FAN L, Yang Y, Chi C, Ma X, et al
    Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castration-resistant prostate cancer.
    Prostate. 2019 Jan 6. doi: 10.1002/pros.23762.
    PubMed     Text format     Abstract available
    
    
    
17. PAPANICOLAU-SENGOS A, Yang Y, Pabla S, Lenzo FL, et al
    Identification of targets for prostate cancer immunotherapy.
    Prostate. 2019 Jan 6. doi: 10.1002/pros.23756.
    PubMed     Text format     Abstract available
    
    
    
18. HATANAKA Y, de Velasco MA, Oki T, Shimizu N, et al
    HOXA10 expression profiling in prostate cancer.
    Prostate. 2019 Jan 6. doi: 10.1002/pros.23761.
    PubMed     Text format     Abstract available
    
    
    
19. ZHAO M, Qi M, Li X, Hu J, et al
    CUL4B/miR-33b/C-MYC axis promotes prostate cancer progression.
    Prostate. 2019 Jan 4. doi: 10.1002/pros.23754.
    PubMed     Text format     Abstract available
    
    
    
20. BROADFIELD LA, Marcinko K, Tsakiridis E, Zacharidis PG, et al
    Salicylate enhances the response of prostate cancer to radiotherapy.
    Prostate. 2019 Jan 4. doi: 10.1002/pros.23755.
    PubMed     Text format     Abstract available
    
    
    December 2018
21. TSUMURA H, Ishiyama H, Tabata KI, Sekiguchi A, et al
    Long-term outcomes of combining prostate brachytherapy and metastasis-directed radiotherapy in newly diagnosed oligometastatic prostate cancer: A retrospective cohort study.
    Prostate. 2018 Dec 26. doi: 10.1002/pros.23757.
    PubMed     Text format     Abstract available
    
    
    
22. MATEUS PAM, Kido LA, Silva RS, Cagnon VHA, et al
    Association of anti-inflammatory and antiangiogenic therapies negatively influences prostate cancer progression in TRAMP mice.
    Prostate. 2018 Dec 25. doi: 10.1002/pros.23758.
    PubMed     Text format     Abstract available
    
    
    
23. DONADIO JLS, Liu L, Freeman VL, Ekoue DN, et al
    Interaction of NKX3.1 and SELENOP genotype with prostate cancer recurrence.
    Prostate. 2018 Dec 23. doi: 10.1002/pros.23752.
    PubMed     Text format     Abstract available
    
    
    
24. IWAMOTO H, Izumi K, Natsagdorj A, Naito R, et al
    Coffee diterpenes kahweol acetate and cafestol synergistically inhibit the proliferation and migration of prostate cancer cells.
    Prostate. 2018 Dec 19. doi: 10.1002/pros.23753.
    PubMed     Text format     Abstract available
    
    
    
25. JOHNG D, Torga G, Ewing CM, Jin K, et al
    HOXB13 interaction with MEIS1 modifies proliferation and gene expression in prostate cancer.
    Prostate. 2018 Dec 17. doi: 10.1002/pros.23747.
    PubMed     Text format     Abstract available
    
    
    
26. BARBAUD M, Frindel M, Ferrer L, Le Thiec M, et al
    68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes.
    Prostate. 2018 Dec 14. doi: 10.1002/pros.23751.
    PubMed     Text format     Abstract available
    
    
    
27. ADAMO H, Hammarsten P, Hagglof C, Dahl Scherdin T, et al
    Prostate cancer induces C/EBPbeta expression in surrounding epithelial cells which relates to tumor aggressiveness and patient outcome.
    Prostate. 2018 Dec 11. doi: 10.1002/pros.23749.
    PubMed     Text format     Abstract available
    
    
    
28. ZEDAN AH, Hansen TF, Assenholt J, Madsen JS, et al
    Circulating miRNAs in localized/locally advanced prostate cancer patients after radical prostatectomy and radiotherapy.
    Prostate. 2018 Dec 9. doi: 10.1002/pros.23748.
    PubMed     Text format     Abstract available
    
    
    November 2018
29. ERLANDSSON A, Carlsson J, Lundholm M, Falt A, et al
    M2 macrophages and regulatory T cells in lethal prostate cancer.
    Prostate. 2018 Nov 30. doi: 10.1002/pros.23742.
    PubMed     Text format     Abstract available
    
    
    
30. MAJERA D, Skrott Z, Bouchal J, Bartkova J, et al
    Targeting genotoxic and proteotoxic stress-response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram.
    Prostate. 2018 Nov 29. doi: 10.1002/pros.23741.
    PubMed     Text format     Abstract available
    
    
    
31. KRUEGER TE, Thorek DLJ, Meeker AK, Isaacs JT, et al
    Tumor-infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer?
    Prostate. 2018 Nov 28. doi: 10.1002/pros.23738.
    PubMed     Text format     Abstract available
    
    
    
32. COHEN M, Amir S, Golan M, Ben-Neriah Y, et al
    beta-TrCP upregulates HIF-1 in prostate cancer cells.
    Prostate. 2018 Nov 28. doi: 10.1002/pros.23746.
    PubMed     Text format     Abstract available
    
    
    
33. MIYAKE M, Tanaka N, Hori S, Ohnishi S, et al
    Dual benefit of supplementary oral 5-aminolevulinic acid to pelvic radiotherapy in a syngenic prostate cancer model.
    Prostate. 2018 Nov 18. doi: 10.1002/pros.23740.
    PubMed     Text format     Abstract available
    
    
    
34. GIRI VN, Hegarty SE, Hyatt C, O'Leary E, et al
    Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing.
    Prostate. 2018 Nov 18. doi: 10.1002/pros.23739.
    PubMed     Text format     Abstract available
    
    
    
35. ALANEE S, Holland B, Clemons J, Dynda D, et al
    Death due to sepsis in patients diagnosed with prostate cancer.
    Prostate. 2018 Nov 18. doi: 10.1002/pros.23735.
    PubMed     Text format     Abstract available
    
    
    
36. GIULIANELLI R, Nardoni S, Bruzzese D, Falavolti C, et al
    Urotensin II receptor expression in prostate cancer patients: A new possible marker.
    Prostate. 2018 Nov 8. doi: 10.1002/pros.23734.
    PubMed     Text format     Abstract available
    
    
    October 2018
37. MIYAHIRA AK, Den RB, Carlo MI, de Leeuw R, et al
    Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting.
    Prostate. 2018 Oct 31. doi: 10.1002/pros.23729.
    PubMed     Text format     Abstract available
    
    
    
38. LAVOIE JM, Zou K, Khalaf D, Eigl BJ, et al
    Clinical effectiveness of docetaxel for castration-sensitive prostate cancer in a real-world population-based analysis.
    Prostate. 2018 Oct 28. doi: 10.1002/pros.23733.
    PubMed     Text format     Abstract available
    
    
    
39. SUER I, Guzel E, Karatas OF, Creighton CJ, et al
    MicroRNAs as prognostic markers in prostate cancer.
    Prostate. 2018 Oct 21. doi: 10.1002/pros.23731.
    PubMed     Text format     Abstract available
    
    
    
40. ESKRA JN, Schlicht MJ, Bosland MC
    Lack of combination effects of soy isoflavones and taxane chemotherapy of castration-resistant prostate cancer.
    Prostate. 2018 Oct 21. doi: 10.1002/pros.23727.
    PubMed     Text format     Abstract available
    
    
    
41. KRANZBUHLER B, Salemi S, Mortezavi A, Sulser T, et al
    Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
    Prostate. 2018 Oct 21. doi: 10.1002/pros.23725.
    PubMed     Text format     Abstract available
    
    
    
42. SEKINO Y, Oue N, Mukai S, Shigematsu Y, et al
    Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients.
    Prostate. 2018 Oct 16. doi: 10.1002/pros.23728.
    PubMed     Text format     Abstract available
    
    
    
43. ERYILMAZ IE, Aytac Vuruskan B, Kaygisiz O, Egeli U, et al
    RNA-based markers in biopsy cores with atypical small acinar proliferation: Predictive effect of T2E fusion positivity and MMP-2 upregulation for a subsequent prostate cancer diagnosis.
    Prostate. 2018 Oct 7. doi: 10.1002/pros.23724.
    PubMed     Text format     Abstract available
    
    
    
44. WADOSKY KM, Shourideh M, Goodrich DW, Koochekpour S, et al
    Riluzole induces AR degradation via endoplasmic reticulum stress pathway in androgen-dependent and castration-resistant prostate cancer cells.
    Prostate. 2018 Oct 2. doi: 10.1002/pros.23719.
    PubMed     Text format     Abstract available
    
    
    September 2018
45. JAIN S, Dash P, Minz AP, Satpathi S, et al
    Lipopolysaccharide (LPS) enhances prostate cancer metastasis potentially through NF-kappaB activation and recurrent dexamethasone administration fails to suppress it in vivo.
    Prostate. 2018 Sep 27. doi: 10.1002/pros.23722.
    PubMed     Text format     Abstract available
    
    
    
46. WANG J, Lu Z, Wu C, Li Y, et al
    Evaluation of the anticancer and anti-metastasis effects of novel synthetic sodium channel blockers in prostate cancer cells in vitro and in vivo.
    Prostate. 2018 Sep 21. doi: 10.1002/pros.23711.
    PubMed     Text format     Abstract available
    
    
    
47. ROBERTO D, Klotz LH, Venkateswaran V
    Cannabinoid WIN 55,212-2 induces cell cycle arrest and apoptosis, and inhibits proliferation, migration, invasion, and tumor growth in prostate cancer in a cannabinoid-receptor 2 dependent manner.
    Prostate. 2018 Sep 21. doi: 10.1002/pros.23720.
    PubMed     Text format     Abstract available
    
    
    
48. LIU J, Ding D, Jiang Z, Du T, et al
    Long non-coding RNA CCAT1/miR-148a/PKCzeta prevents cell migration of prostate cancer by altering macrophage polarization.
    Prostate. 2018 Sep 16. doi: 10.1002/pros.23716.
    PubMed     Text format     Abstract available
    
    
    
49. CHEN Z, Jiang Q, Zhu P, Chen Y, et al
    NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer.
    Prostate. 2018 Sep 3. doi: 10.1002/pros.23709.
    PubMed     Text format     Abstract available
    
    
    
50. DUGUE PA, Dowty JG, Joo JE, Wong EM, et al
    Heritable methylation marks associated with breast and prostate cancer risk.
    Prostate. 2018;78:962-969.
    PubMed     Text format     Abstract available
    
    
    
51. VAN DUIJN PW, Marques RB, Ziel-van der Made ACJ, van Zoggel HJAA, et al
    Tumor heterogeneity, aggressiveness, and immune cell composition in a novel syngeneic PSA-targeted Pten knockout mouse prostate cancer (MuCaP) model.
    Prostate. 2018;78:1013-1023.
    PubMed     Text format     Abstract available
    
    
    August 2018
52. LI Y, Zhang Q, Lovnicki J, Chen R, et al
    SRRM4 gene expression correlates with neuroendocrine prostate cancer.
    Prostate. 2018 Aug 28. doi: 10.1002/pros.23715.
    PubMed     Text format     Abstract available
    
    
    
53. PALLER C, Pu H, Begemann DE, Wade CA, et al
    TGF-beta receptor I inhibitor enhances response to enzalutamide in a pre-clinical model of advanced prostate cancer.
    Prostate. 2018 Aug 28. doi: 10.1002/pros.23708.
    PubMed     Text format     Abstract available
    
    
    
54. XIE W, Stopsack KH, Drouin SJ, Fu H, et al
    Association of genetic variation of the six gene prognostic model for castration-resistant prostate cancer with survival.
    Prostate. 2018 Aug 23. doi: 10.1002/pros.23712.
    PubMed     Text format     Abstract available
    
    
    
55. TOMMASI S, Pilato B, Carella C, Lasorella A, et al
    Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression.
    Prostate. 2018 Aug 23. doi: 10.1002/pros.23710.
    PubMed     Text format     Abstract available
    
    
    
56. ALANEE S, El-Zawahry A, Dynda D, Dabaja A, et al
    A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16sRNA gene analysis.
    Prostate. 2018 Aug 16. doi: 10.1002/pros.23713.
    PubMed     Text format     Abstract available
    
    
    
57. WEISSENRIEDER JS, Reilly JE, Neighbors JD, Hohl RJ, et al
    Inhibiting geranylgeranyl diphosphate synthesis reduces nuclear androgen receptor signaling and neuroendocrine differentiation in prostate cancer cell models.
    Prostate. 2018 Aug 14. doi: 10.1002/pros.23707.
    PubMed     Text format     Abstract available
    
    
    
58. HUANG W, Su X, Yan W, Kong Z, et al
    Overexpression of AR-regulated lncRNA TMPO-AS1 correlates with tumor progression and poor prognosis in prostate cancer.
    Prostate. 2018 Aug 13. doi: 10.1002/pros.23700.
    PubMed     Text format     Abstract available
    
    
    
59. CUI F, Hu J, Ning S, Tan J, et al
    Overexpression of MCM10 promotes cell proliferation and predicts poor prognosis in prostate cancer.
    Prostate. 2018 Aug 10. doi: 10.1002/pros.23703.
    PubMed     Text format     Abstract available
    
    
    
60. GEVARIYA N, Besancon M, Robitaille K, Picard V, et al
    Omega-3 fatty acids decrease prostate cancer progression associated with an anti-tumor immune response in eugonadal and castrated mice.
    Prostate. 2018 Aug 2. doi: 10.1002/pros.23706.
    PubMed     Text format     Abstract available
    
    
    
61. NAVONE NM, van Weerden WM, Vessella RL, Williams ED, et al
    Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.
    Prostate. 2018 Aug 2. doi: 10.1002/pros.23701.
    PubMed     Text format     Abstract available
    
    
    July 2018
62. CHAKRAVARTHI BVSK, Chandrashekar DS, Hodigere Balasubramanya SA, Robinson AD, et al
    Wnt receptor Frizzled 8 is a target of ERG in prostate cancer.
    Prostate. 2018 Jul 26. doi: 10.1002/pros.23704.
    PubMed     Text format     Abstract available
    
    
    
63. KOIDE H, Kimura T, Inaba H, Sato S, et al
    Comparison of ERG and SPINK1 expression among incidental and metastatic prostate cancer in Japanese men.
    Prostate. 2018 Jul 26. doi: 10.1002/pros.23705.
    PubMed     Text format     Abstract available
    
    
    
64. WU Y, Yu H, Zheng SL, Feng B, et al
    Germline mutations in PPFIBP2 are associated with lethal prostate cancer.
    Prostate. 2018 Jul 24. doi: 10.1002/pros.23697.
    PubMed     Text format     Abstract available
    
    
    
65. LIU C, Zhu Y, Su H, Xu X, et al
    Relationship between PSA kinetics and Tc-99m HYNIC PSMA SPECT/CT detection rates of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
    Prostate. 2018 Jul 19. doi: 10.1002/pros.23696.
    PubMed     Text format     Abstract available
    
    
    
66. YAMAKAWA T, Waer C, Itakura K
    AT-rich interactive domain 5B regulates androgen receptor transcription in human prostate cancer cells.
    Prostate. 2018 Jul 19. doi: 10.1002/pros.23699.
    PubMed     Text format     Abstract available
    
    
    
67. ROOT A, Ebhardt HA
    A two-drug combination simulation study for metastatic castrate resistant prostate cancer.
    Prostate. 2018 Jul 19. doi: 10.1002/pros.23694.
    PubMed     Text format     Abstract available
    
    
    
68. YANG T, Jing Y, Dong J, Yu X, et al
    Regulation of ELL2 stability and polyubiquitination by EAF2 in prostate cancer cells.
    Prostate. 2018 Jul 15. doi: 10.1002/pros.23695.
    PubMed     Text format     Abstract available
    
    
    
69. HE W, Li J
    Exendin-4 enhances radiation response of prostate cancer.
    Prostate. 2018 Jul 15. doi: 10.1002/pros.23687.
    PubMed     Text format     Abstract available
    
    
    
70. LI D, Tian G, Wang J, Zhao LY, et al
    Inhibition of androgen receptor transactivation function by adenovirus type 12 E1A undermines prostate cancer cell survival.
    Prostate. 2018 Jul 15. doi: 10.1002/pros.23689.
    PubMed     Text format     Abstract available
    
    
    
71. DORAI T, Shah A, Summers F, Mathew R, et al
    NRH:quinone oxidoreductase 2 (NQO2) and glutaminase (GLS) both play a role in large extracellular vesicles (LEV) formation in preclinical LNCaP-C4-2B prostate cancer model of progressive metastasis.
    Prostate. 2018 Jul 15. doi: 10.1002/pros.23693.
    PubMed     Text format     Abstract available
    
    
    
72. TWEEDLE MF, Ding H, Drost WT, Dowell J, et al
    Development of an orthotopic canine prostate cancer model expressing human GRPr.
    Prostate. 2018 Jul 11. doi: 10.1002/pros.23686.
    PubMed     Text format     Abstract available
    
    
    
73. LIM DM, Gulati R, Aleshin-Guendel S, Gawne A, et al
    Undetectable prostate-specific antigen after short-course androgen deprivation therapy for biochemically recurrent patients correlates with metastasis-free survival and prostate cancer-specific survival.
    Prostate. 2018 Jul 10. doi: 10.1002/pros.23666.
    PubMed     Text format     Abstract available
    
    
    
74. ROGASCH JM, Cash H, Zschaeck S, Elezkurtaj S, et al
    Ga-68-PSMA PET/CT in treatment-naive patients with prostate cancer: Which clinical parameters and risk stratification systems best predict PSMA-positive metastases?
    Prostate. 2018 Jul 5. doi: 10.1002/pros.23685.
    PubMed     Text format     Abstract available
    
    
    June 2018
75. ZHAO S, Leonardson A, Geybels MS, McDaniel AS, et al
    A five-CpG DNA methylation score to predict metastatic-lethal outcomes in men treated with radical prostatectomy for localized prostate cancer.
    Prostate. 2018 Jun 28. doi: 10.1002/pros.23667.
    PubMed     Text format     Abstract available
    
    
    
76. COOK SF, Fiandalo MV, Watt DS, Wu Y, et al
    Mathematical modeling of intracrine androgen metabolism in prostate cancer: Methodological aspects.
    Prostate. 2018 Jun 25. doi: 10.1002/pros.23665.
    PubMed     Text format     Abstract available
    
    
    
77. HELFAND BT, Chen H, Fantus RJ, Conran CA, et al
    Differences in inherited risk among relatives of hereditary prostate cancer patients using genetic risk score.
    Prostate. 2018 Jun 19. doi: 10.1002/pros.23664.
    PubMed     Text format     Abstract available
    
    
    
78. BARATA P, Emamekhoo H, Mendiratta P, Koshkin V, et al
    Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
    Prostate. 2018 Jun 7. doi: 10.1002/pros.23663.
    PubMed     Text format     Abstract available
    
    
    
79. CHOUDHURY AD, Gray KP, Supko JG, Harshman LC, et al
    A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer.
    Prostate. 2018 Jun 7. doi: 10.1002/pros.23662.
    PubMed     Text format     Abstract available
    
    
    
80. CHAKRAVARTHI BVSK, Goswami MT, Pathi SS, Dodson M, et al
    Expression and role of PAICS, a de novo purine biosynthetic gene in prostate cancer.
    Prostate. 2018;78:693-694.
    PubMed     Text format    
    
    
    
81. FURRER MA, Vilaseca A, Corradi RB, Boxler S, et al
    Repeat prostate biopsies prior to radical prostatectomy do not impact erectile function recovery and mid- to long-term continence.
    Prostate. 2018;78:631-636.
    PubMed     Text format     Abstract available
    
    
    
82. THOMAS-JARDIN SE, Kanchwala MS, Jacob J, Merchant S, et al
    Identification of an IL-1-induced gene expression pattern in AR(+) PCa cells that mimics the molecular phenotype of AR(-) PCa cells.
    Prostate. 2018;78:595-606.
    PubMed     Text format     Abstract available
    
    
    
83. OJALILL M, Rappu P, Siljamaki E, Taimen P, et al
    The composition of prostate core matrisome in vivo and in vitro unveiled by mass spectrometric analysis.
    Prostate. 2018;78:583-594.
    PubMed     Text format     Abstract available
    
    
    May 2018
84. MIYAHIRA AK, Soule HR
    The 24th Annual Prostate Cancer Foundation scientific retreat report.
    Prostate. 2018 May 15. doi: 10.1002/pros.23651.
    PubMed     Text format     Abstract available
    
    
    
85. AL SALEH HA, Haas-Neill S, Al-Hashimi A, Kapoor A, et al
    Thrombotic characteristics of extracellular vesicles derived from prostate cancer cells.
    Prostate. 2018 May 15. doi: 10.1002/pros.23653.
    PubMed     Text format     Abstract available
    
    
    
86. JARVIS C, Nelius T, Martinez-Marin D, Sennoune SR, et al
    Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
    Prostate. 2018 May 10. doi: 10.1002/pros.23647.
    PubMed     Text format     Abstract available
    
    
    
87. MUNOZ-MORENO L, Schally AV, Prieto JC, Carmena MJ, et al
    Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer.
    Prostate. 2018 May 10. doi: 10.1002/pros.23648.
    PubMed     Text format     Abstract available
    
    
    
88. TINAY I, Tan M, Gui B, Werner L, et al
    Functional roles and potential clinical application of miRNA-345-5p in prostate cancer.
    Prostate. 2018 May 10. doi: 10.1002/pros.23650.
    PubMed     Text format     Abstract available
    
    
    
89. ALLOTT EH, Farnan L, Steck SE, Song L, et al
    Statin use, high cholesterol and prostate cancer progression; results from HCaP-NC.
    Prostate. 2018 May 1. doi: 10.1002/pros.23644.
    PubMed     Text format     Abstract available
    
    
    
90. MIYAHIRA AK, Pienta KJ, Morris MJ, Bander NH, et al
    Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group.
    Prostate. 2018 May 1. doi: 10.1002/pros.23642.
    PubMed     Text format     Abstract available
    
    
    
91. CAMPOLINA-SILVA GH, Maria BT, Mahecha GAB, Oliveira CA, et al
    Reduced vitamin D receptor (VDR) expression and plasma vitamin D levels are associated with aging-related prostate lesions.
    Prostate. 2018;78:532-546.
    PubMed     Text format     Abstract available
    
    
    April 2018
92. ISHII K, Sasaki T, Iguchi K, Kajiwara S, et al
    Interleukin-6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation.
    Prostate. 2018 Apr 29. doi: 10.1002/pros.23643.
    PubMed     Text format     Abstract available
    
    
    
93. FRANCINI E, Gray KP, Xie W, Shaw GK, et al
    Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
    Prostate. 2018 Apr 29. doi: 10.1002/pros.23645.
    PubMed     Text format     Abstract available
    
    
    
94. BEYENE DA, Naab TJ, Kanarek NF, Apprey V, et al
    Differential expression of Annexin 2, SPINK1, and Hsp60 predict progression of prostate cancer through bifurcated WHO Gleason score categories in African American men.
    Prostate. 2018 Apr 22. doi: 10.1002/pros.23537.
    PubMed     Text format     Abstract available
    
    
    
95. BAYAT H, Narouie B, Ziaee SM, Mowla SJ, et al
    Two long non-coding RNAs, Prcat17.3 and Prcat38, could efficiently discriminate benign prostate hyperplasia from prostate cancer.
    Prostate. 2018 Apr 19. doi: 10.1002/pros.23538.
    PubMed     Text format     Abstract available
    
    
    
96. MILLER EA, Pinsky PF, Black A, Andriole GL, et al
    Secondary prostate cancer screening outcomes by race in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening Trial.
    Prostate. 2018 Apr 17. doi: 10.1002/pros.23540.
    PubMed     Text format     Abstract available
    
    
    
97. POMPE RS, Tilki D, Preisser F, Leyh-Bannurah SR, et al
    Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages.
    Prostate. 2018 Apr 16. doi: 10.1002/pros.23519.
    PubMed     Text format     Abstract available
    
    
    
98. KOSTOVA MB, Brennen WN, Lopez D, Anthony L, et al
    PSA-alpha-2-macroglobulin complex is enzymatically active in the serum of patients with advanced prostate cancer and can degrade circulating peptide hormones.
    Prostate. 2018 Apr 16. doi: 10.1002/pros.23539.
    PubMed     Text format     Abstract available
    
    
    
99. GIRI VN, Obeid E, Hegarty SE, Gross L, et al
    Understanding of multigene test results among males undergoing germline testing for inherited prostate cancer: Implications for genetic counseling.
    Prostate. 2018 Apr 14. doi: 10.1002/pros.23535.
    PubMed     Text format     Abstract available
    
    
    
100. MORI K, Kimura T, Ito K, Onuma H, et al
     Earlier use of androgen receptor-axis-targeted drugs may improve overall survival in patients with non-metastatic castration-resistant prostate cancer.
     Prostate. 2018 Apr 10. doi: 10.1002/pros.23534.
     PubMed     Text format     Abstract available
     
     
     
101. BRATT O
     RE: Preissner F, et al. extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. The Prostate. 2018;1-7.
     Prostate. 2018 Apr 6. doi: 10.1002/pros.23520.
     PubMed     Text format    
     
     
     
102. KRANZBUHLER B, Salemi S, Umbricht CA, Muller C, et al
     Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells.
     Prostate. 2018 Apr 6. doi: 10.1002/pros.23522.
     PubMed     Text format     Abstract available
     
     
     
103. PRENCIPE M, Fabre A, Murphy TB, Vargyas E, et al
     Role of serum response factor expression in prostate cancer biochemical recurrence.
     Prostate. 2018 Apr 2. doi: 10.1002/pros.23516.
     PubMed     Text format     Abstract available
     
     
     
104. PREISSER F, Bandini M, Graefen M, Tilki D, et al
     Reply to the letter to the editor: RE: Preisser F, et al. Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. The Prostate. 2018;1-7.
     Prostate. 2018 Apr 2. doi: 10.1002/pros.23521.
     PubMed     Text format    
     
     
     March 2018
105. GAO X, Mao YH, Xiao C, Li K, et al
     Calpain-2 triggers prostate cancer metastasis via enhancing CRMP4 promoter methylation through NF-kappaB/DNMT1 signaling pathway.
     Prostate. 2018 Mar 30. doi: 10.1002/pros.23512.
     PubMed     Text format     Abstract available
     
     
     
106. BABCOOK MA, Akgul M, Margevicius S, MacLennan GT, et al
     Ser-486/491 phosphorylation and inhibition of AMPKalpha activity is positively associated with Gleason score, metastasis, and castration-resistance in prostate cancer: A retrospective clinical study.
     Prostate. 2018 Mar 26. doi: 10.1002/pros.23515.
     PubMed     Text format     Abstract available
     
     
     
107. BRENNEN WN, Isaacs JT
     The what, when, and why of human prostate cancer xenografts.
     Prostate. 2018 Mar 24. doi: 10.1002/pros.23510.
     PubMed     Text format     Abstract available
     
     
     
108. LINXWEILER J, Korbel C, Muller A, Hammer M, et al
     A novel mouse model of human prostate cancer to study intraprostatic tumor growth and the development of lymph node metastases.
     Prostate. 2018 Mar 24. doi: 10.1002/pros.23508.
     PubMed     Text format     Abstract available
     
     
     
109. AKINBOYE ES, Rogers OC, Isaacs JT
     2-fluoro-5-maleimidobenzoic acid-linked albumin drug (MAD) delivery for selective systemic targeting of metastatic prostate cancer.
     Prostate. 2018 Mar 24. doi: 10.1002/pros.23494.
     PubMed     Text format     Abstract available
     
     
     
110. CAMPOS C, Sotomayor P, Jerez D, Gonzalez J, et al
     Exercise and prostate cancer: From basic science to clinical applications.
     Prostate. 2018 Mar 23. doi: 10.1002/pros.23502.
     PubMed     Text format     Abstract available
     
     
     
111. CHEN J, Oromendia C, Halpern JA, Ballman KV, et al
     National trends in management of localized prostate cancer: A population based analysis 2004-2013.
     Prostate. 2018 Mar 14. doi: 10.1002/pros.23496.
     PubMed     Text format     Abstract available
     
     
     
112. WANG Y, Xu H, Si L, Li Q, et al
     MiR-206 inhibits proliferation and migration of prostate cancer cells by targeting CXCL11.
     Prostate. 2018 Mar 14. doi: 10.1002/pros.23468.
     PubMed     Text format     Abstract available
     
     
     
113. DAVID SN, Arnold Egloff SA, Goyal R, Clark PE, et al
     MAGI2 is an independent predictor of biochemical recurrence in prostate cancer.
     Prostate. 2018 Mar 14. doi: 10.1002/pros.23506.
     PubMed     Text format     Abstract available
     
     
     
114. CARLETON NM, Zhu G, Gorbounov M, Miller MC, et al
     PBOV1 as a potential biomarker for more advanced prostate cancer based on protein and digital histomorphometric analysis.
     Prostate. 2018 Mar 9. doi: 10.1002/pros.23499.
     PubMed     Text format     Abstract available
     
     
     
115. KEAM SP, Gulati T, Gamell C, Caramia F, et al
     Exploring the oncoproteomic response of human prostate cancer to therapeutic radiation using data-independent acquisition (DIA) mass spectrometry.
     Prostate. 2018 Mar 9. doi: 10.1002/pros.23500.
     PubMed     Text format     Abstract available
     
     
     
116. HAYMAN J, Phillips R, Chen D, Perin J, et al
     Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality.
     Prostate. 2018 Mar 9. doi: 10.1002/pros.23507.
     PubMed     Text format     Abstract available
     
     
     
117. WU Y, Yu H, Zheng SL, Na R, et al
     A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer.
     Prostate. 2018 Mar 9. doi: 10.1002/pros.23505.
     PubMed     Text format     Abstract available
     
     
     
118. OKEGAWA T, Ninomiya N, Masuda K, Nakamura Y, et al
     AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.
     Prostate. 2018 Mar 5. doi: 10.1002/pros.23501.
     PubMed     Text format     Abstract available
     
     
     
119. BERGSTROM SH, Jaremo H, Nilsson M, Adamo HH, et al
     Prostate tumors downregulate microseminoprotein-beta (MSMB) in the surrounding benign prostate epithelium and this response is associated with tumor aggressiveness.
     Prostate. 2018;78:257-265.
     PubMed     Text format     Abstract available
     
     
     February 2018
120. COPELAND BT, Pal SK, Bolton EC, Jones JO, et al
     The androgen receptor malignancy shift in prostate cancer.
     Prostate. 2018 Feb 23. doi: 10.1002/pros.23497.
     PubMed     Text format     Abstract available
     
     
     
121. ITO K, Kimura T, Onuma H, Tabata R, et al
     Does docetaxel prolong survival of patients with non-metastatic castration-resistant prostate cancer?
     Prostate. 2018 Feb 23. doi: 10.1002/pros.23493.
     PubMed     Text format     Abstract available
     
     
     
122. MACCINI MA, Westfall NJ, Van Bokhoven A, Lucia MS, et al
     The effect of digital rectal exam on the 4Kscore for aggressive prostate cancer.
     Prostate. 2018 Feb 19. doi: 10.1002/pros.23495.
     PubMed     Text format     Abstract available
     
     
     
123. PREISSER F, Bandini M, Marchioni M, Nazzani S, et al
     Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion.
     Prostate. 2018 Feb 19. doi: 10.1002/pros.23491.
     PubMed     Text format     Abstract available
     
     
     
124. SHOU J, Zhang Q, Wang S, Zhang D, et al
     The prognosis of different distant metastases pattern in prostate cancer: A population based retrospective study.
     Prostate. 2018 Feb 13. doi: 10.1002/pros.23492.
     PubMed     Text format     Abstract available
     
     
     
125. DE LAERE B, Oeyen S, Van Oyen P, Ghysel C, et al
     Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.
     Prostate. 2018 Feb 12. doi: 10.1002/pros.23488.
     PubMed     Text format     Abstract available
     
     
     
126. SILVA JAF, Bruni-Cardoso A, Augusto TM, Damas-Souza DM, et al
     Macrophage roles in the clearance of apoptotic cells and control of inflammation in the prostate gland after castration.
     Prostate. 2018;78:95-103.
     PubMed     Text format     Abstract available
     
     
     
127. RODRIGO MAM, Strmiska V, Horackova E, Buchtelova H, et al
     Sarcosine influences apoptosis and growth of prostate cells via cell-type specific regulation of distinct sets of genes.
     Prostate. 2018;78:104-112.
     PubMed     Text format     Abstract available
     
     
     
128. PAZIEWSKA A, Mikula M, Dabrowska M, Kulecka M, et al
     Candidate diagnostic miRNAs that can detect cancer in prostate biopsy.
     Prostate. 2018;78:178-185.
     PubMed     Text format     Abstract available
     
     
     January 2018
129. JIANG X, Huang Y, Liang X, Jiang F, et al
     Metastatic prostate cancer-associated P62 inhibits autophagy flux and promotes epithelial to mesenchymal transition by sustaining the level of HDAC6.
     Prostate. 2018 Jan 31. doi: 10.1002/pros.23487.
     PubMed     Text format     Abstract available
     
     
     
130. KARLSSON T, Sundar R, Widmark A, Landstrom M, et al
     Osteoblast-derived factors promote metastatic potential in human prostate cancer cells, in part via non-canonical transforming growth factor beta (TGFbeta) signaling.
     Prostate. 2018 Jan 31. doi: 10.1002/pros.23489.
     PubMed     Text format     Abstract available
     
     
     
131. MCDONALD AC, Vira M, Shen J, Sanda M, et al
     Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer.
     Prostate. 2018 Jan 31. doi: 10.1002/pros.23485.
     PubMed     Text format     Abstract available
     
     
     
132. WANG L, Kim D, Wise JTF, Shi X, et al
     p62 as a therapeutic target for inhibition of autophagy in prostate cancer.
     Prostate. 2018 Jan 25. doi: 10.1002/pros.23483.
     PubMed     Text format     Abstract available
     
     
     
133. WURNSCHIMMEL C, Grande P, Moschini M, Ferrari M, et al
     Accuracy of standardized 12-core template biopsies versus non-standardized biopsies for detection of Epstein Grade 5 prostate cancer regarding the histology of the prostatectomy specimen.
     Prostate. 2018 Jan 25. doi: 10.1002/pros.23480.
     PubMed     Text format     Abstract available
     
     
     
134. ISAACSSON VELHO P, Silberstein JL, Markowski MC, Luo J, et al
     Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.
     Prostate. 2018 Jan 25. doi: 10.1002/pros.23484.
     PubMed     Text format     Abstract available
     
     
     
135. MIKI J, Yanagisawa T, Tsuzuki S, Mori K, et al
     Anatomical localization and clinical impact of sentinel lymph nodes based on patterns of pelvic lymphatic drainage in clinically localized prostate cancer.
     Prostate. 2018 Jan 25. doi: 10.1002/pros.23486.
     PubMed     Text format     Abstract available
     
     
     
136. DU Z, Lubmawa A, Gundell S, Wan P, et al
     Genetic risk of prostate cancer in ugandan men.
     Prostate. 2018 Jan 21. doi: 10.1002/pros.23481.
     PubMed     Text format     Abstract available
     
     
     
137. BEEBE-DIMMER JL, Zuhlke KA, Johnson AM, Liesman D, et al
     Rare germline mutations in African American men diagnosed with early-onset prostate cancer.
     Prostate. 2018 Jan 21. doi: 10.1002/pros.23464.
     PubMed     Text format     Abstract available
     
     
     
138. HUANG H, Wang Q, Du T, Lin C, et al
     Matrine inhibits the progression of prostate cancer by promoting expression of GADD45B.
     Prostate. 2018 Jan 21. doi: 10.1002/pros.23469.
     PubMed     Text format     Abstract available
     
     
     
139. SU Z, Zhang M, Xu M, Li X, et al
     MicroRNA181c inhibits prostate cancer cell growth and invasion by targeting multiple ERK signaling pathway components.
     Prostate. 2018 Jan 16. doi: 10.1002/pros.23478.
     PubMed     Text format     Abstract available
     
     
     
140. KIMBROUGH-ALLAH MN, Millena AC, Khan SA
     Differential role of PTEN in transforming growth factor beta (TGF-beta) effects on proliferation and migration in prostate cancer cells.
     Prostate. 2018 Jan 16. doi: 10.1002/pros.23482.
     PubMed     Text format     Abstract available
     
     
     
141. HENDRIKS RJ, Dijkstra S, Smit FP, Vandersmissen J, et al
     Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients.
     Prostate. 2018 Jan 12. doi: 10.1002/pros.23477.
     PubMed     Text format     Abstract available
     
     
     
142. XU L, Shen M, Chen X, Zhu R, et al
     Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.
     Prostate. 2018 Jan 12. doi: 10.1002/pros.23479.
     PubMed     Text format     Abstract available
     
     
     
143. AZUMA T
     Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer: A retrospective study.
     Prostate. 2018 Jan 8. doi: 10.1002/pros.23470.
     PubMed     Text format    
     
     
     
144. ALBITAR M, Ma W, Lund L, Shahbaba B, et al
     Prostatectomy-based validation of combined urine and plasma test for predicting high grade prostate cancer.
     Prostate. 2018 Jan 8. doi: 10.1002/pros.23473.
     PubMed     Text format     Abstract available
     
     
     
145. EKOUE DN, Ansong E, Liu L, Macias V, et al
     Correlations of SELENOF and SELENOP genotypes with serum selenium levels and prostate cancer.
     Prostate. 2018 Jan 5. doi: 10.1002/pros.23471.
     PubMed     Text format     Abstract available
     
     
     
146. LIN HM, Lee BY, Castillo L, Spielman C, et al
     Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.
     Prostate. 2018 Jan 5. doi: 10.1002/pros.23476.
     PubMed     Text format     Abstract available
     
     
     
147. TYAGI P, Motley SS, Koyama T, Kashyap M, et al
     Molecular correlates in urine for the obesity and prostatic inflammation of BPH/LUTS patients.
     Prostate. 2018;78:17-24.
     PubMed     Text format     Abstract available
     
     
     December 2017
148. VAN DER TOOM EE, Groot VP, Glavaris SA, Gemenetzis G, et al
     Analogous detection of circulating tumor cells using the AccuCyte((R)) -CyteFinder((R)) system and ISET system in patients with locally advanced and metastatic prostate cancer.
     Prostate. 2017 Dec 29. doi: 10.1002/pros.23474.
     PubMed     Text format     Abstract available
     
     
     
149. FAN L, Wang R, Chi C, Cai W, et al
     Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
     Prostate. 2017 Dec 29. doi: 10.1002/pros.23465.
     PubMed     Text format     Abstract available
     
     
     
150. MCLEOD AB, Stice JP, Wardell SE, Alley HM, et al
     Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
     Prostate. 2017 Dec 15. doi: 10.1002/pros.23467.
     PubMed     Text format     Abstract available
     
     
     
151. ZUMSTEG ZS, Chen Z, Howard LE, Amling CL, et al
     Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH.
     Prostate. 2017;77:1592-1600.
     PubMed     Text format     Abstract available
     
     
     
152. ZHOU CK, Stanczyk FZ, Hafi M, Veneroso CC, et al
     Circulating and intraprostatic sex steroid hormonal profiles in relation to male pattern baldness and chest hair density among men diagnosed with localized prostate cancers.
     Prostate. 2017;77:1573-1582.
     PubMed     Text format     Abstract available
     
     
     
153. BAUER SR, Van Blarigan EL, Stampfer MJ, Chan JM, et al
     Mediterranean diet after prostate cancer diagnosis and urinary and sexual functioning: The health professionals follow-up study.
     Prostate. 2017 Dec 1. doi: 10.1002/pros.23457.
     PubMed     Text format     Abstract available
     
     
     
154. ANDO T, Nishiyama T, Takizawa I, Miyashiro Y, et al
     A carbon 21 steroidal metabolite from progestin, 20beta-hydroxy-5alpha-dihydroprogesterone, stimulates the androgen receptor in prostate cancer cells.
     Prostate. 2017 Dec 1. doi: 10.1002/pros.23460.
     PubMed     Text format     Abstract available
     
     
     
155. FIANDALO MV, Wilton JH, Mantione KM, Wrzosek C, et al
     Serum-free complete medium, an alternative medium to mimic androgen deprivation in human prostate cancer cell line models.
     Prostate. 2017 Dec 1. doi: 10.1002/pros.23459.
     PubMed     Text format     Abstract available
     
     
     November 2017
156. YAN G, Ru Y, Wu K, Yan F, et al
     GOLM1 promotes prostate cancer progression through activating PI3K-AKT-mTOR signaling.
     Prostate. 2017 Nov 27. doi: 10.1002/pros.23461.
     PubMed     Text format     Abstract available
     
     
     
157. CHEN H, Ewing CM, Zheng S, Grindedaal EM, et al
     Genetic factors influencing prostate cancer risk in Norwegian men.
     Prostate. 2017 Nov 27. doi: 10.1002/pros.23453.
     PubMed     Text format     Abstract available
     
     
     
158. JOSHU CE, Peskoe SB, Heaphy CM, Kenfield SA, et al
     Current or recent smoking is associated with more variable telomere length in prostate stromal cells and prostate cancer cells.
     Prostate. 2017 Nov 22. doi: 10.1002/pros.23462.
     PubMed     Text format     Abstract available
     
     
     
159. TSUI KH, Chang YL, Feng TH, Hou CP, et al
     Capillarisin blocks prostate-specific antigen expression on activation of androgen receptor in prostate carcinoma cells.
     Prostate. 2017 Nov 22. doi: 10.1002/pros.23463.
     PubMed     Text format     Abstract available
     
     
     
160. FACINA CH, Campos SGP, Goncalves BF, Goes RM, et al
     Long-term oral exposure to safe dose of bisphenol A in association with high-fat diet stimulate the prostatic lesions in a rodent model for prostate cancer.
     Prostate. 2017 Nov 17. doi: 10.1002/pros.23458.
     PubMed     Text format     Abstract available
     
     
     
161. GHASHGHAEI M, Paliouras M, Heravi M, Bekerat H, et al
     Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells.
     Prostate. 2017 Nov 14. doi: 10.1002/pros.23445.
     PubMed     Text format     Abstract available
     
     
     
162. KALSBEEK AMF, Chan EKF, Grogan J, Petersen DC, et al
     Altered mitochondrial genome content signals worse pathology and prognosis in prostate cancer.
     Prostate. 2017 Nov 14. doi: 10.1002/pros.23440.
     PubMed     Text format     Abstract available
     
     
     
163. COARFA C, Florentin D, Putluri N, Ding Y, et al
     Influence of the neural microenvironment on prostate cancer.
     Prostate. 2017 Nov 13. doi: 10.1002/pros.23454.
     PubMed     Text format     Abstract available
     
     
     
164. TAT D, Kenfield SA, Cowan JE, Broering JM, et al
     Milk and other dairy foods in relation to prostate cancer recurrence: Data from the cancer of the prostate strategic urologic research endeavor (CaPSURE).
     Prostate. 2017 Nov 6. doi: 10.1002/pros.23441.
     PubMed     Text format     Abstract available
     
     
     
165. MARTINO T, Kudrolli TA, Kumar B, Salviano I, et al
     The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress.
     Prostate. 2017 Nov 6. doi: 10.1002/pros.23455.
     PubMed     Text format     Abstract available
     
     
     
166. CHENG HH, Plets M, Li H, Higano CS, et al
     Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer.
     Prostate. 2017 Nov 6. doi: 10.1002/pros.23452.
     PubMed     Text format     Abstract available
     
     
     
167. XIAO H, Wang J, Yan W, Cui Y, et al
     GLUT1 regulates cell glycolysis and proliferation in prostate cancer.
     Prostate. 2017 Nov 6. doi: 10.1002/pros.23448.
     PubMed     Text format     Abstract available
     
     
     
168. SCHMIDKONZ C, Hollweg C, Beck M, Reinfelder J, et al
     99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer.
     Prostate. 2017 Nov 6. doi: 10.1002/pros.23444.
     PubMed     Text format     Abstract available
     
     
     
169. DAVIDSSON S, Andren O, Ohlson AL, Carlsson J, et al
     FOXP3+ regulatory T cells in normal prostate tissue, postatrophic hyperplasia, prostatic intraepithelial neoplasia, and tumor histological lesions in men with and without prostate cancer.
     Prostate. 2017 Nov 6. doi: 10.1002/pros.23442.
     PubMed     Text format     Abstract available
     
     
     
170. BONKHOFF H
     Estrogen receptor signaling in prostate cancer: Implications for carcinogenesis and tumor progression.
     Prostate. 2017 Nov 2. doi: 10.1002/pros.23446.
     PubMed     Text format     Abstract available
     
     
     
171. KATO M, Kimura K, Hirakawa A, Kobayashi Y, et al
     Prognostic parameter for high risk prostate cancer patients at initial presentation.
     Prostate. 2017 Nov 2. doi: 10.1002/pros.23438.
     PubMed     Text format     Abstract available
     
     
     
172. TJON-KON-FAT LA, Lundholm M, Schroder M, Wurdinger T, et al
     Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response to abiraterone in castration resistant patients.
     Prostate. 2017 Nov 2. doi: 10.1002/pros.23443.
     PubMed     Text format     Abstract available
     
     
     
173. NESBITT H, Worthington J, Errington RJ, Patterson LH, et al
     The unidirectional hypoxia-activated prodrug OCT1002 inhibits growth and vascular development in castrate-resistant prostate tumors.
     Prostate. 2017;77:1539-1547.
     PubMed     Text format     Abstract available
     
     
     October 2017
174. STARK TW, Hensley PJ, Spear A, Pu H, et al
     Predictive value of epithelial-mesenchymal-transition (EMT) signature and PARP-1 in prostate cancer radioresistance.
     Prostate. 2017 Oct 23. doi: 10.1002/pros.23435.
     PubMed     Text format     Abstract available
     
     
     
175. WOODS-BURNHAM L, Basu A, Cajigas-Du Ross CK, Love A, et al
     The 22Rv1 prostate cancer cell line carries mixed genetic ancestry: Implications for prostate cancer health disparities research using pre-clinical models.
     Prostate. 2017 Oct 14. doi: 10.1002/pros.23437.
     PubMed     Text format     Abstract available
     
     
     
176. LI E, Liu L, Li F, Luo L, et al
     PSCA promotes prostate cancer proliferation and cell-cycle progression by up-regulating c-Myc.
     Prostate. 2017 Oct 2. doi: 10.1002/pros.23432.
     PubMed     Text format     Abstract available
     
     
     
177. ABEDINPOUR P, Baron VT, Chrastina A, Rondeau G, et al
     Plumbagin improves the efficacy of androgen deprivation therapy in prostate cancer: A pre-clinical study.
     Prostate. 2017 Oct 2. doi: 10.1002/pros.23428.
     PubMed     Text format     Abstract available
     
     
     
178. SHI X, Peng Y, Du X, Liu H, et al
     Estradiol promotes epithelial-to-mesenchymal transition in human benign prostatic epithelial cells.
     Prostate. 2017;77:1424-1437.
     PubMed     Text format     Abstract available
     
     
     
179. HAYASHI T, Fujita K, Nojima S, Hayashi Y, et al
     Peripheral blood monocyte count reflecting tumor-infiltrating macrophages is a predictive factor of adverse pathology in radical prostatectomy specimens.
     Prostate. 2017;77:1383-1388.
     PubMed     Text format     Abstract available
     
     
     September 2017
180. BURDELSKI C, Shihada R, Hinsch A, Angerer A, et al
     High-Level Glyoxalase 1 (GLO1) expression is linked to poor prognosis in prostate cancer.
     Prostate. 2017 Sep 19. doi: 10.1002/pros.23431.
     PubMed     Text format     Abstract available
     
     
     
181. MIYAHIRA AK, Cheng HH, Abida W, Ellis L, et al
     Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting.
     Prostate. 2017 Sep 18. doi: 10.1002/pros.23424.
     PubMed     Text format     Abstract available
     
     
     
182. TSUMURA H, Ishiyama H, Tabata KI, Katsumata H, et al
     Impact of five-tiered Gleason grade groups on prognostic prediction in clinical stage T3 prostate cancer undergoing high-dose-rate brachytherapy.
     Prostate. 2017 Sep 14. doi: 10.1002/pros.23430.
     PubMed     Text format     Abstract available
     
     
     
183. KANAYAMA M, Hayano T, Koebis M, Maeda T, et al
     Hyperactive mTOR induces neuroendocrine differentiation in prostate cancer cell with concurrent up-regulation of IRF1.
     Prostate. 2017 Sep 14. doi: 10.1002/pros.23425.
     PubMed     Text format     Abstract available
     
     
     
184. PEDRAZA-AREVALO S, Hormaechea-Agulla D, Gomez-Gomez E, Requena MJ, et al
     Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer.
     Prostate. 2017 Sep 14. doi: 10.1002/pros.23426.
     PubMed     Text format     Abstract available
     
     
     
185. STROMVALL K, Sundkvist K, Ljungberg B, Halin Bergstrom S, et al
     Reduced number of CD169+ macrophages in pre-metastatic regional lymph nodes is associated with subsequent metastatic disease in an animal model and with poor outcome in prostate cancer patients.
     Prostate. 2017 Sep 7. doi: 10.1002/pros.23407.
     PubMed     Text format     Abstract available
     
     
     
186. YANG CS, Melhuish TA, Spencer A, Ni L, et al
     The protein kinase C super-family member PKN is regulated by mTOR and influences differentiation during prostate cancer progression.
     Prostate. 2017 Sep 6. doi: 10.1002/pros.23400.
     PubMed     Text format     Abstract available
     
     
     
187. VINCENEUX A, Bruyere F, Haillot O, Charles T, et al
     Ductal adenocarcinoma of the prostate: Clinical and biological profiles.
     Prostate. 2017;77:1242-1250.
     PubMed     Text format     Abstract available
     
     
     August 2017
188. GINSBURG KB, Elshafei A, Yu C, Jones JS, et al
     Avoidance of androgen deprivation therapy in radiorecurrent prostate cancer as a clinically meaningful endpoint for salvage cryoablation.
     Prostate. 2017 Aug 29. doi: 10.1002/pros.23406.
     PubMed     Text format     Abstract available
     
     
     
189. SOEKMADJI C, Corcoran NM, Oleinikova I, Jovanovic L, et al
     Extracellular vesicles for personalized therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer.
     Prostate. 2017 Aug 29. doi: 10.1002/pros.23403.
     PubMed     Text format     Abstract available
     
     
     
190. HENDRIKS RJ, van der Leest MMG, Dijkstra S, Barentsz JO, et al
     A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection.
     Prostate. 2017 Aug 29. doi: 10.1002/pros.23401.
     PubMed     Text format     Abstract available
     
     
     
191. SUH JH, Park JH, Lee C, Moon KC, et al
     Intrafocal heterogeneity of ERG protein expression and gene fusion pattern in prostate cancer.
     Prostate. 2017 Aug 28. doi: 10.1002/pros.23405.
     PubMed     Text format     Abstract available
     
     
     
192. LIU L, Li E, Luo L, Zhao S, et al
     PSCA regulates IL-6 expression through p38/NF-kappaB signaling in prostate cancer.
     Prostate. 2017 Aug 28. doi: 10.1002/pros.23399.
     PubMed     Text format     Abstract available
     
     
     
193. MIYATA Y, Nakamura Y, Yasuda T, Matsuo T, et al
     Neoadjuvant hormonal therapy for low-risk prostate cancer induces biochemical recurrence after radical prostatectomy via increased lymphangiogenesis-related parameters.
     Prostate. 2017 Aug 28. doi: 10.1002/pros.23402.
     PubMed     Text format     Abstract available
     
     
     
194. DONG B, Fan L, Wang Y, Chi C, et al
     Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy-naive metastatic castration-resistant prostate cancer.
     Prostate. 2017 Aug 14. doi: 10.1002/pros.23397.
     PubMed     Text format     Abstract available
     
     
     
195. STRUSS WJ, Tan Z, Zachkani P, Moskalev I, et al
     Magnetically-actuated drug delivery device (MADDD) for minimally invasive treatment of prostate cancer: An in vivo animal pilot study.
     Prostate. 2017 Aug 8. doi: 10.1002/pros.23395.
     PubMed     Text format     Abstract available
     
     
     
196. PALLER CJ, Cole AP, Partin AW, Carducci MA, et al
     Risk factors for metastatic prostate cancer: A sentinel event case series.
     Prostate. 2017 Aug 8. doi: 10.1002/pros.23396.
     PubMed     Text format     Abstract available
     
     
     
197. VAN NESTE L, Groskopf J, Grizzle WE, Adams GW, et al
     Epigenetic risk score improves prostate cancer risk assessment.
     Prostate. 2017 Aug 1. doi: 10.1002/pros.23385.
     PubMed     Text format     Abstract available
     
     
     
198. HARSHMAN LC, Werner L, Tripathi A, Wang X, et al
     The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer.
     Prostate. 2017 Aug 1. doi: 10.1002/pros.23390.
     PubMed     Text format     Abstract available
     
     
     July 2017
199. FAN L, Wang X, Chi C, Wang Y, et al
     Prognostic nutritional index predicts initial response to treatment and prognosis in metastatic castration-resistant prostate cancer patients treated with abiraterone.
     Prostate. 2017 Jul 28. doi: 10.1002/pros.23381.
     PubMed     Text format     Abstract available
     
     
     
200. SUN G, Huang R, Zhang X, Shen P, et al
     The impact of multifocal perineural invasion on biochemical recurrence and timing of adjuvant androgen-deprivation therapy in high-risk prostate cancer following radical prostatectomy.
     Prostate. 2017 Jul 27. doi: 10.1002/pros.23388.
     PubMed     Text format     Abstract available
     
     
     
201. SHARPE B, Alghezi DA, Cattermole C, Beresford M, et al
     A subset of high Gleason grade prostate carcinomas contain a large burden of prostate cancer syndecan-1 positive stromal cells.
     Prostate. 2017 Jul 26. doi: 10.1002/pros.23391.
     PubMed     Text format     Abstract available
     
     
     
202. LIN X, Chen Z, Gao P, Gao Z, et al
     TEX15: A DNA repair gene associated with prostate cancer risk in Han Chinese.
     Prostate. 2017 Jul 21. doi: 10.1002/pros.23387.
     PubMed     Text format     Abstract available
     
     
     
203. AI J, Tai PWL, Lu Y, Li J, et al
     Characterization of adenoviral transduction profile in prostate cancer cells and normal prostate tissue.
     Prostate. 2017 Jul 20. doi: 10.1002/pros.23386.
     PubMed     Text format     Abstract available
     
     
     
204. TODENHOFER T, Hennenlotter J, Keller G, Neumann T, et al
     Effect of radical prostatectomy on levels of cancer related epitopes in circulating macrophages of patients with clinically localized prostate cancer.
     Prostate. 2017 Jul 20. doi: 10.1002/pros.23384.
     PubMed     Text format     Abstract available
     
     
     
205. BREEN KJ, O'Neill A, Murphy L, Fan Y, et al
     Investigating the role of the IGF axis as a predictor of biochemical recurrence in prostate cancer patients post-surgery.
     Prostate. 2017 Jul 20. doi: 10.1002/pros.23389.
     PubMed     Text format     Abstract available
     
     
     
206. CHEN H, Na R, Packiam VT, Conran CA, et al
     Reclassification of prostate cancer risk using sequentially identified SNPs: Results from the REDUCE trial.
     Prostate. 2017 Jul 2. doi: 10.1002/pros.23369.
     PubMed     Text format     Abstract available
     
     
     
207. DE BARI B, Stish B, Ball MW, Habboush Y, et al
     Adult prostatic sarcoma: A contemporary multicenter Rare Cancer Network study.
     Prostate. 2017;77:1160-1166.
     PubMed     Text format     Abstract available
     
     
     
208. RODRIGUES TM, Mitre AI, da Silva LFF, Castilho LN, et al
     Periprostatic innervation: New issues based on segmental analysis of 10 human cadaver pelvic blocs.
     Prostate. 2017;77:1151-1159.
     PubMed     Text format     Abstract available
     
     
     
209. BOKHORST LP, Roobol MJ, Bangma CH, van Leenders GJ, et al
     Effect of pathologic revision and Ki67 and ERG immunohistochemistry on predicting radical prostatectomy outcome in men initially on active surveillance.
     Prostate. 2017;77:1137-1143.
     PubMed     Text format     Abstract available
     
     
     June 2017
210. LAWAL IO, Ankrah AO, Mokgoro NP, Vorster M, et al
     Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.
     Prostate. 2017 Jun 26. doi: 10.1002/pros.23379.
     PubMed     Text format     Abstract available
     
     
     
211. CRUMBAKER M, Gurney H
     Dose considerations for anti-cancer drugs in metastatic prostate cancer.
     Prostate. 2017 Jun 26. doi: 10.1002/pros.23378.
     PubMed     Text format     Abstract available
     
     
     
212. HE C, Duan S, Dong L, Wang Y, et al
     Characterization of a novel p110beta-specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells.
     Prostate. 2017 Jun 20. doi: 10.1002/pros.23377.
     PubMed     Text format     Abstract available
     
     
     
213. CAI B, Chen W, Pan Y, Chen H, et al
     Inhibition of microRNA-500 has anti-cancer effect through its conditional downstream target of TFPI in human prostate cancer.
     Prostate. 2017 Jun 20. doi: 10.1002/pros.23361.
     PubMed     Text format     Abstract available
     
     
     
214. XU Y, Qin S, An T, Tang Y, et al
     MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method.
     Prostate. 2017 Jun 15. doi: 10.1002/pros.23376.
     PubMed     Text format     Abstract available
     
     
     
215. ZHAO R, Sun F, Bei X, Wang X, et al
     Upregulation of the long non-coding RNA FALEC promotes proliferation and migration of prostate cancer cell lines and predicts prognosis of PCa patients.
     Prostate. 2017 Jun 6. doi: 10.1002/pros.23367.
     PubMed     Text format     Abstract available
     
     
     
216. ARMSTRONG CM, Liu C, Lou W, Lombard AP, et al
     MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.
     Prostate. 2017;77:1020-1028.
     PubMed     Text format     Abstract available
     
     
     
217. GONZAGA ACR, Campolina-Silva GH, Werneck-Gomes H, Moura-Cordeiro JD, et al
     Profile of cell proliferation and apoptosis activated by the intrinsic and extrinsic pathways in the prostate of aging rats.
     Prostate. 2017;77:937-948.
     PubMed     Text format     Abstract available
     
     
     
218. AJIBOYE AS, Esopi D, Yegnasubramanian S, Denmeade SR, et al
     Androgen Receptor Splice Variants Are Not Substrates of Nonsense-Mediated Decay.
     Prostate. 2017;77:829-837.
     PubMed     Text format     Abstract available
     
     
     
219. KIDO LA, Montico F, Vendramini-Costa DB, Pilli RA, et al
     Goniothalamin and Celecoxib Effects During Aging: Targeting Pro-Inflammatory Mediators in Chemoprevention of Prostatic Disorders.
     Prostate. 2017;77:838-848.
     PubMed     Text format     Abstract available
     
     
     
220. SHARIF A, Malhotra NR, Acosta AM, Kajdacsy-Balla AA, et al
     The Development of Prostate Adenocarcinoma in a Transgender Male to Female Patient: Could Estrogen Therapy Have Played a Role?
     Prostate. 2017;77:824-828.
     PubMed     Text format     Abstract available
     
     
     May 2017
221. MORI K, Kimura T, Onuma H, Kimura S, et al
     Lactate dehydrogenase predicts combined progression-free survival after sequential therapy with abiraterone and enzalutamide for patients with castration-resistant prostate cancer.
     Prostate. 2017 May 30. doi: 10.1002/pros.23373.
     PubMed     Text format     Abstract available
     
     
     
222. KIM Y, Park SE, Moon JW, Kim BM, et al
     Downregulation of androgen receptors by NaAsO2 via inhibition of AKT-NF-kappaB and HSP90 in castration resistant prostate cancer.
     Prostate. 2017 May 30. doi: 10.1002/pros.23370.
     PubMed     Text format     Abstract available
     
     
     
223. NUNEZ BRAGAYRAC LA, Murekeyisoni C, Vacchio MJ, Attwood K, et al
     Blinded review of archival radical prostatectomy specimens supports that contemporary Gleason score 6 prostate cancer lacks metastatic potential.
     Prostate. 2017 May 26. doi: 10.1002/pros.23364.
     PubMed     Text format     Abstract available
     
     
     
224. IRIZARRY-RAMIREZ M, Kittles RA, Wang X, Salgado-Montilla J, et al
     Genetic ancestry and prostate cancer susceptibility SNPs in Puerto Rican and African American men.
     Prostate. 2017 May 24. doi: 10.1002/pros.23368.
     PubMed     Text format     Abstract available
     
     
     
225. MIYAHIRA AK, Soule HR
     The 23rd Annual Prostate Cancer Foundation Scientific Retreat report.
     Prostate. 2017 May 14. doi: 10.1002/pros.23366.
     PubMed     Text format     Abstract available
     
     
     
226. NOVAKOVA Z, Foss CA, Copeland BT, Morath V, et al
     Novel Monoclonal Antibodies Recognizing Human Prostate-Specific Membrane Antigen (PSMA) as Research and Theranostic Tools.
     Prostate. 2017;77:749-764.
     PubMed     Text format     Abstract available
     
     
     
227. HUANG H, Du T, Zhang Y, Lai Y, et al
     Elevation of SHARPIN Protein Levels in Prostate Adenocarcinomas Promotes Metastasis and Impairs Patient Survivals.
     Prostate. 2017;77:718-728.
     PubMed     Text format     Abstract available
     
     
     
228. OLSON BM, Bradley ES, Sawicki T, Zhong W, et al
     Safety and Immunological Efficacy of a DNA Vaccine Encoding the Androgen Receptor Ligand-Binding Domain (AR-LBD).
     Prostate. 2017;77:812-821.
     PubMed     Text format     Abstract available
     
     
     
229. POMPE RS, Davis-Bondarenko H, Zaffuto E, Tian Z, et al
     Population-Based Validation of the 2014 ISUP Gleason Grade Groups in Patients Treated With Radical Prostatectomy, Brachytherapy, External Beam Radiation, or no Local Treatment.
     Prostate. 2017;77:686-693.
     PubMed     Text format     Abstract available
     
     
     
230. MELITI A, Sadimin E, Diolombi M, Khani F, et al
     Accuracy of Grading Gleason Score 7 Prostatic Adenocarcinoma on Needle Biopsy: Influence of Percent Pattern 4 and Other Histological Factors.
     Prostate. 2017;77:681-685.
     PubMed     Text format     Abstract available
     
     
     
231. PIERCONTI F, Martini M, Cenci T, Petrone GL, et al
     SOCS3 Immunohistochemical Expression Seems to Support the 2005 and 2014 International Society of Urological Pathology (ISUP) Modified Gleason Grading System.
     Prostate. 2017;77:597-603.
     PubMed     Text format     Abstract available
     
     
     
232. HENNING JD, Karamchandani JM, Bonachea LA, Bunker CH, et al
     Elevated Serum PSA is Associated With Human Herpesvirus 8 Infection and Increased Circulating Cytokine Levels in Men From Tobago.
     Prostate. 2017;77:617-624.
     PubMed     Text format     Abstract available
     
     
     
233. BRETT SI, Lucien F, Guo C, Williams KC, et al
     Immunoaffinity based methods are superior to kits for purification of prostate derived extracellular vesicles from plasma samples.
     Prostate. 2017;77:1335-1343.
     PubMed     Text format     Abstract available
     
     
     April 2017
234. SCHALLY AV, Block NL, Rick FG
     Discovery of LHRH and development of LHRH analogs for prostate cancer treatment.
     Prostate. 2017 Apr 27. doi: 10.1002/pros.23360.
     PubMed     Text format     Abstract available
     
     
     
235. CONTEDUCA V, Caffo O, Lolli C, Aieta M, et al
     Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone.
     Prostate. 2017 Apr 20. doi: 10.1002/pros.23357.
     PubMed     Text format     Abstract available
     
     
     
236. JIA L, Gui B, Zheng D, Decker KF, et al
     Androgen receptor-regulated miRNA-193a-3p targets AJUBA to promote prostate cancer cell migration.
     Prostate. 2017 Apr 19. doi: 10.1002/pros.23356.
     PubMed     Text format     Abstract available
     
     
     
237. TANG B, Han CT, Gan HL, Zhang GM, et al
     Smoking increased the risk of prostate cancer with grade group >/= 4 and intraductal carcinoma in a prospective biopsy cohort.
     Prostate. 2017 Apr 19. doi: 10.1002/pros.23354.
     PubMed     Text format     Abstract available
     
     
     
238. PELLEGRINI KL, Patil D, Douglas KJS, Lee G, et al
     Detection of prostate cancer-specific transcripts in extracellular vesicles isolated from post-DRE urine.
     Prostate. 2017 Apr 17. doi: 10.1002/pros.23355.
     PubMed     Text format     Abstract available
     
     
     
239. DE CARVALHO TM, Heijnsdijk EAM, de Koning HJ
     When should active surveillance for prostate cancer stop if no progression is detected?
     Prostate. 2017 Apr 17. doi: 10.1002/pros.23352.
     PubMed     Text format     Abstract available
     
     
     
240. GONCALVES BF, de Campos SG, Goes RM, Scarano WR, et al
     Dual action of high estradiol doses on MNU-induced prostate neoplasms in a rodent model with high serum testosterone: Protective effect and emergence of unstable epithelial microenvironment.
     Prostate. 2017 Apr 12. doi: 10.1002/pros.23353.
     PubMed     Text format     Abstract available
     
     
     
241. NAKATA D, Koyama R, Nakayama K, Kitazawa S, et al
     Glycogen synthase kinase-3 inhibitors suppress the AR-V7-mediated transcription and selectively inhibit cell growth in AR-V7-positive prostate cancer cells.
     Prostate. 2017 Apr 10. doi: 10.1002/pros.23351.
     PubMed     Text format     Abstract available
     
     
     
242. BEAUVAL JB, Cabarrou B, Gandaglia G, Patard PM, et al
     External validation of a nomogram for identification of pathologically favorable disease in intermediate risk prostate cancer patients.
     Prostate. 2017 Apr 2. doi: 10.1002/pros.23348.
     PubMed     Text format     Abstract available
     
     
     March 2017
243. RUNDLE A, Wang Y, Sadasivan S, Chitale DA, et al
     Larger men have larger prostates: Detection bias in epidemiologic studies of obesity and prostate cancer risk.
     Prostate. 2017 Mar 27. doi: 10.1002/pros.23350.
     PubMed     Text format     Abstract available
     
     
     
244. HABL G, Sauter K, Schiller K, Dewes S, et al
     68 Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment.
     Prostate. 2017 Mar 20. doi: 10.1002/pros.23347.
     PubMed     Text format     Abstract available
     
     
     
245. WINCHESTER DA, Till C, Goodman PJ, Tangen CM, et al
     Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial.
     Prostate. 2017 Mar 20. doi: 10.1002/pros.23346.
     PubMed     Text format     Abstract available
     
     
     
246. TOLKACH Y, Eminaga O, Wotzel F, Huss S, et al
     Blind Biobanking of the Prostatectomy Specimen: Critical Evaluation of the Existing Techniques and Development of the New 4-Level Tissue Extraction Model With High Sampling Efficacy.
     Prostate. 2017;77:396-405.
     PubMed     Text format     Abstract available
     
     
     November 2016
247. REGIS L, Planas J, Carles J, Maldonado X, et al
     Free Testosterone During Androgen Deprivation Therapy Predicts Castration-Resistant Progression Better Than Total Testosterone.
     Prostate. 2016 Nov 1. doi: 10.1002/pros.23256.
     PubMed     Text format     Abstract available
     
     
     July 2016
248. GALHEIGO MR, Cruz AR, Cabral AS, Faria PR, et al
     Role of the TNF-alpha receptor type 1 on prostate carcinogenesis in knockout mice.
     Prostate. 2016;76:917-26.
     PubMed     Text format     Abstract available
     
     
     
249. SARTOR O, Hoskin P, Coleman RE, Nilsson S, et al
     Chemotherapy following radium-223 dichloride treatment in ALSYMPCA.
     Prostate. 2016;76:905-16.
     PubMed     Text format     Abstract available
     
     
     June 2016
250. GERRIN SJ, Sowalsky AG, Balk SP, Ye H, et al
     Mutation profiling indicates high grade prostatic intraepithelial neoplasia as distant precursors of adjacent invasive prostatic adenocarcinoma.
     Prostate. 2016 Jun 8. doi: 10.1002/pros.23212.
     PubMed     Text format     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: